Symbols / ACRS $3.76 +0.53%
ACRS Chart
About
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 455.29M |
| Enterprise Value | 362.39M | Income | -64.92M | Sales | 7.83M |
| Book/sh | 0.85 | Cash/sh | 0.75 | Dividend Yield | — |
| Payout | 0.00% | Employees | 69 | IPO | — |
| P/E | — | Forward P/E | -4.96 | PEG | — |
| P/S | 58.18 | P/B | 4.40 | P/C | — |
| EV/EBITDA | -4.89 | EV/Sales | 46.31 | Quick Ratio | 3.36 |
| Current Ratio | 3.36 | Debt/Eq | 2.05 | LT Debt/Eq | — |
| EPS (ttm) | -0.53 | EPS next Y | -0.76 | EPS Growth | — |
| Revenue Growth | -85.90% | Earnings | 2026-05-07 | ROA | -24.32% |
| ROE | -50.20% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -17.25% | Profit Margin | 0.00% | Shs Outstand | 121.09M |
| Shs Float | 97.80M | Short Float | 4.59% | Short Ratio | 4.09 |
| Short Interest | — | 52W High | 4.89 | 52W Low | 1.05 |
| Beta | 0.87 | Avg Volume | 2.25M | Volume | 123.46K |
| Target Price | $8.29 | Recom | Strong_buy | Prev Close | $3.74 |
| Price | $3.76 | Change | 0.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.29
Mean price target
2. Current target
$3.76
Latest analyst target
3. DCF / Fair value
$-4.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.76
Low
$3.00
High
$16.00
Mean
$8.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2026-01-21 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-28 | init | Wedbush | — → Outperform | $8 |
| 2025-05-14 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-09 | main | Scotiabank | Sector Outperform → Sector Outperform | $9 |
| 2025-03-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $15 |
| 2024-12-23 | up | HC Wainwright & Co. | Neutral → Buy | $20 |
| 2024-11-19 | up | Leerink Partners | Market Perform → Outperform | $7 |
| 2024-11-19 | up | Jefferies | Hold → Buy | $7 |
| 2024-11-19 | up | BTIG | Neutral → Buy | $8 |
| 2024-11-18 | up | Piper Sandler | Neutral → Overweight | $13 |
| 2024-09-17 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-07-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-01-22 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-01-11 | down | BTIG | Buy → Neutral | — |
| 2023-12-29 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
- Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat ue, 17 Mar 2026 11
- What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? - Yahoo Finance ue, 21 Oct 2025 07
- Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st Mon, 26 Jan 2026 08
- Aclaris tests experimental asthma antibody in new human trial - Stock Titan ue, 24 Feb 2026 08
- Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia Mon, 16 Mar 2026 12
- Aclaris Therapeutics Raises $20 Million in Equity Financing - TipRanks hu, 12 Mar 2026 01
- Can Aclaris Therapeutics Stock Hold Up When Markets Turn? - Trefis Sun, 21 Dec 2025 08
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat Sat, 14 Mar 2026 09
- Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView Wed, 11 Mar 2026 20
- Aclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND Application - Quiver Quantitative hu, 26 Feb 2026 08
- Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
- New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan ue, 06 Jan 2026 08
- Experimental atopic dermatitis drug begins new safety trial in patients - Stock Titan Mon, 12 Jan 2026 08
- Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance Sun, 12 Oct 2025 07
- Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat Sat, 07 Mar 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2375 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-02-27 00:00:00 | D | nan |
| 1 | 20875 | — | — | LOEROP JAMES | Officer | — | 2026-02-03 00:00:00 | D | nan |
| 2 | 22025 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-02-03 00:00:00 | D | nan |
| 3 | 18675 | — | — | DAVIS HUGH M. | President | — | 2026-02-03 00:00:00 | D | nan |
| 4 | 63475 | — | — | WALKER NEAL | Chief Executive Officer | — | 2026-02-03 00:00:00 | D | nan |
| 5 | 33500 | — | — | LOEROP JAMES | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 6 | 14750 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-01-30 00:00:00 | D | nan |
| 7 | 91900 | — | — | LOEROP JAMES | Officer | — | 2026-01-02 00:00:00 | D | nan |
| 8 | 94450 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-01-02 00:00:00 | D | nan |
| 9 | 29150 | — | — | WALKER NEAL | Chief Executive Officer | — | 2026-01-02 00:00:00 | D | nan |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 78.30K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -67.51M | 39.60M | -134.41M | -79.66M |
| TotalUnusualItems | -2.30M | -89.41M | 18.96M | -4.70M |
| TotalUnusualItemsExcludingGoodwill | -2.30M | -89.41M | 18.96M | -4.70M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -64.92M | -132.06M | -88.48M | -86.91M |
| ReconciledDepreciation | 454.00K | 807.00K | 863.00K | 797.00K |
| ReconciledCostOfRevenue | 7.28M | 15.46M | 18.08M | 11.96M |
| EBITDA | -69.81M | -49.81M | -115.45M | -84.36M |
| EBIT | -70.26M | -50.61M | -116.31M | -85.15M |
| NetInterestIncome | 7.64M | 7.95M | ||
| InterestIncome | 7.64M | 7.95M | ||
| NormalizedIncome | -62.62M | -42.66M | -107.36M | -82.21M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -64.92M | -132.06M | -88.48M | -86.91M |
| TotalExpenses | 78.09M | 69.33M | 147.56M | 114.91M |
| TotalOperatingIncomeAsReported | -76.38M | -141.93M | -97.36M | -89.85M |
| DilutedAverageShares | 77.30M | 69.81M | 65.21M | 56.73M |
| BasicAverageShares | 77.30M | 69.81M | 65.21M | 56.73M |
| DilutedEPS | -1.71 | -1.27 | -1.33 | -1.60 |
| BasicEPS | -1.71 | -1.27 | -1.33 | -1.60 |
| DilutedNIAvailtoComStockholders | -64.92M | -132.06M | -88.48M | -86.91M |
| NetIncomeCommonStockholders | -64.92M | -132.06M | -88.48M | -86.91M |
| NetIncome | -64.92M | -132.06M | -88.48M | -86.91M |
| NetIncomeIncludingNoncontrollingInterests | -64.92M | -132.06M | -88.48M | -86.91M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | -64.92M | -132.06M | -88.48M | -86.91M |
| TaxProvision | 0.00 | -367.00K | 0.00 | 0.00 |
| PretaxIncome | -64.92M | -132.06M | -88.85M | -86.91M |
| OtherIncomeExpense | -2.30M | -89.41M | 27.47M | -1.75M |
| OtherNonOperatingIncomeExpenses | 7.95M | 8.51M | 2.95M | -1.14M |
| SpecialIncomeCharges | -2.30M | -89.41M | 18.96M | -4.70M |
| OtherSpecialCharges | 86.91M | 6.63M | ||
| WriteOff | 0.00 | 1.31M | 0.00 | |
| ImpairmentOfCapitalAssets | 6.63M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 2.30M | 2.50M | -26.90M | 4.70M |
| NetNonOperatingInterestIncomeExpense | 7.64M | 7.95M | ||
| InterestIncomeNonOperating | 7.64M | 7.95M | ||
| OperatingIncome | -70.26M | -50.61M | -116.31M | -85.15M |
| OperatingExpense | 70.80M | 53.88M | 129.48M | 102.95M |
| OtherOperatingExpenses | -3.81M | -1.91M | ||
| ResearchAndDevelopment | 52.65M | 33.59M | 98.38M | 77.81M |
| SellingGeneralAndAdministration | 21.97M | 22.20M | 31.10M | 25.13M |
| GeneralAndAdministrativeExpense | 21.97M | 22.20M | 31.10M | 25.13M |
| OtherGandA | 7.05M | 8.63M | 10.80M | 8.96M |
| SalariesAndWages | 14.92M | 13.57M | 20.30M | 16.17M |
| GrossProfit | 542.00K | 3.26M | 13.17M | 17.79M |
| CostOfRevenue | 7.28M | 15.46M | 18.08M | 11.96M |
| TotalRevenue | 7.83M | 18.72M | 31.25M | 29.75M |
| OperatingRevenue | 7.83M | 18.72M | 31.25M | 29.50M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 120.50M | 107.85M | 70.89M | 66.69M |
| ShareIssued | 120.50M | 107.85M | 70.89M | 66.69M |
| TotalDebt | 426.00K | 684.00K | 693.00K | |
| TangibleBookValue | 103.08M | 155.55M | 157.18M | 190.65M |
| InvestedCapital | 103.08M | 155.55M | 157.18M | 197.62M |
| WorkingCapital | 67.67M | 94.36M | 97.90M | 209.61M |
| NetTangibleAssets | 103.08M | 155.55M | 157.18M | 190.65M |
| CapitalLeaseObligations | 426.00K | 684.00K | 693.00K | |
| CommonStockEquity | 103.08M | 155.55M | 157.18M | 197.62M |
| TotalCapitalization | 103.08M | 155.55M | 157.18M | 197.62M |
| TotalEquityGrossMinorityInterest | 103.08M | 155.55M | 157.18M | 197.62M |
| StockholdersEquity | 103.08M | 155.55M | 157.18M | 197.62M |
| GainsLossesNotAffectingRetainedEarnings | 610.00K | 97.00K | -106.00K | -897.00K |
| OtherEquityAdjustments | 610.00K | 97.00K | -106.00K | -897.00K |
| RetainedEarnings | -967.78M | -902.86M | -770.80M | -682.32M |
| AdditionalPaidInCapital | 1.07B | 1.06B | 928.08M | 880.83M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 57.38M | 64.77M | 40.23M | 56.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 28.73M | 33.18M | 9.27M | 35.04M |
| OtherNonCurrentLiabilities | 12.56M | 13.14M | 9.27M | 34.67M |
| NonCurrentDeferredLiabilities | 16.17M | 20.04M | 0.00 | 367.00K |
| NonCurrentDeferredRevenue | 16.17M | 20.04M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 367.00K | 367.00K | |
| CurrentLiabilities | 28.64M | 31.60M | 30.95M | 21.94M |
| OtherCurrentLiabilities | 2.75M | 2.68M | 2.63M | 2.20M |
| CurrentDeferredLiabilities | 3.94M | 7.82M | 0.00 | |
| CurrentDeferredRevenue | 3.94M | 3.89M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 426.00K | 684.00K | 693.00K | |
| CurrentCapitalLeaseObligation | 426.00K | 684.00K | 693.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.30M | 4.98M | 3.91M | 5.29M |
| PayablesAndAccruedExpenses | 16.65M | 16.12M | 24.41M | 13.76M |
| CurrentAccruedExpenses | 3.49M | 11.43M | 15.54M | 3.41M |
| Payables | 13.16M | 4.69M | 8.88M | 10.35M |
| AccountsPayable | 13.16M | 4.69M | 8.88M | 10.35M |
| TotalAssets | 160.46M | 220.33M | 197.41M | 254.60M |
| TotalNonCurrentAssets | 64.14M | 94.38M | 68.55M | 23.05M |
| OtherNonCurrentAssets | 2.77M | 3.07M | 4.16M | 2.73M |
| InvestmentsAndAdvances | 60.61M | 90.30M | 62.77M | 12.24M |
| OtherInvestments | 34.24M | |||
| InvestmentinFinancialAssets | 60.61M | 90.30M | 62.77M | 12.24M |
| AvailableForSaleSecurities | 60.61M | 90.30M | 62.77M | 12.24M |
| GoodwillAndOtherIntangibleAssets | 269.00K | 6.97M | 7.05M | |
| OtherIntangibleAssets | 269.00K | 6.97M | 7.05M | |
| NetPPE | 761.00K | 1.01M | 1.62M | 1.10M |
| AccumulatedDepreciation | -4.80M | -4.16M | -4.04M | -3.39M |
| GrossPPE | 5.81M | 5.78M | 5.13M | 4.73M |
| Leases | 817.00K | 817.00K | 1.12M | 1.12M |
| OtherProperties | 3.14M | 3.15M | 2.01M | 1.60M |
| MachineryFurnitureEquipment | 1.86M | 1.81M | 2.00M | 2.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 96.32M | 125.95M | 128.86M | 231.55M |
| OtherCurrentAssets | 5.57M | 12.36M | 9.45M | 13.49M |
| PrepaidAssets | 12.99M | |||
| Receivables | 318.00K | 298.00K | 484.00K | 623.00K |
| AccountsReceivable | 318.00K | 298.00K | 484.00K | 623.00K |
| CashCashEquivalentsAndShortTermInvestments | 90.75M | 113.59M | 119.11M | 217.57M |
| OtherShortTermInvestments | 70.79M | 89.02M | 79.23M | 172.29M |
| CashAndCashEquivalents | 19.96M | 24.57M | 39.88M | 45.28M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -47.22M | -56.01M | -79.63M | -68.17M |
| RepaymentOfDebt | 0.00 | 0.00 | -11.48M | |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 74.91M | 26.71M | 72.74M |
| CapitalExpenditure | -111.00K | -35.93M | -1.31M | -605.00K |
| EndCashPosition | 19.96M | 24.57M | 39.88M | 45.28M |
| BeginningCashPosition | 24.57M | 39.88M | 45.28M | 27.35M |
| ChangesInCash | -4.61M | -15.31M | -5.40M | 17.93M |
| FinancingCashFlow | -5.86M | 74.54M | 26.71M | 72.87M |
| CashFlowFromContinuingFinancingActivities | -5.86M | 74.54M | 26.71M | 72.87M |
| NetOtherFinancingCharges | -5.86M | -409.00K | -102.00K | -34.00K |
| ProceedsFromStockOptionExercised | 0.00 | 32.00K | 94.00K | 157.00K |
| NetCommonStockIssuance | 0.00 | 74.91M | 26.71M | 72.74M |
| CommonStockIssuance | 0.00 | 74.91M | 26.71M | 72.74M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -11.48M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -11.48M | |
| LongTermDebtPayments | 0.00 | 0.00 | -11.48M | |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 48.37M | -69.77M | 46.22M | 12.63M |
| CashFlowFromContinuingInvestingActivities | 48.37M | -69.77M | 46.22M | 12.63M |
| NetInvestmentPurchaseAndSale | 49.31M | -33.84M | 47.53M | 13.23M |
| SaleOfInvestment | 89.04M | 86.14M | 183.20M | 177.99M |
| PurchaseOfInvestment | -39.73M | -119.98M | -135.68M | -164.75M |
| NetBusinessPurchaseAndSale | -833.00K | 0.00 | 0.00 | |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -833.00K | 0.00 | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -35.81M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -35.81M | 0.00 | |
| NetPPEPurchaseAndSale | -111.00K | -121.00K | -1.31M | -605.00K |
| PurchaseOfPPE | -111.00K | -121.00K | -1.31M | -605.00K |
| OperatingCashFlow | -47.11M | -20.07M | -78.33M | -67.57M |
| CashFlowFromContinuingOperatingActivities | -47.11M | -20.07M | -78.33M | -67.57M |
| ChangeInWorkingCapital | 2.67M | 10.92M | 9.39M | -1.20M |
| ChangeInOtherWorkingCapital | -3.82M | 23.93M | ||
| ChangeInPayablesAndAccruedExpense | 350.00K | -8.13M | 10.52M | 960.00K |
| ChangeInAccruedExpense | -8.10M | -3.94M | 11.99M | 592.00K |
| ChangeInPayable | 8.45M | -4.19M | -1.47M | 368.00K |
| ChangeInAccountPayable | 8.45M | -4.19M | -1.47M | 368.00K |
| ChangeInPrepaidAssets | 6.14M | -4.88M | -1.31M | -2.29M |
| ChangeInReceivables | -20.00K | 186.00K | 139.00K | 149.00K |
| ChangesInAccountReceivables | -20.00K | 186.00K | 139.00K | 149.00K |
| OtherNonCashItems | 2.30M | 89.41M | -20.27M | 4.70M |
| StockBasedCompensation | 12.38M | 10.86M | 20.54M | 15.04M |
| AssetImpairmentCharge | 6.63M | 0.00 | 0.00 | |
| DeferredTax | 0.00 | -367.00K | 0.00 | 0.00 |
| DeferredIncomeTax | 0.00 | -367.00K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 454.00K | 807.00K | 863.00K | 797.00K |
| DepreciationAndAmortization | 454.00K | 807.00K | 863.00K | 797.00K |
| OperatingGainsLosses | 752.00K | |||
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -64.92M | -132.06M | -88.48M | -86.91M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACRS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|